Autoimmune cholangiopathy: The result of consecutive primary biliary cirrhosis and autoimmune hepatitis?
Abstract
Autoimmune cholangiopathy is a recently proposed entity that describes a specific group of patients presenting overlapping features of primary biliary cirrhosis and autoimmune hepatitis, i.e., clinical and/or biochemical cholestasis, high titer antinuclear antibody, negative antimitochondrial antibody, and elevated immunoglobulin G. Liver histology shows primary biliary cirrhosis coexisting with varying degrees of parenchymal inflammation. In addition, these patients achieve remission on corticosteroid therapy. The patient in this report fulfilled the above criteria. However, preceding the autoimmune cholangitis stage, a typical antimitochondrial antibody-positive primary biliary cirrhosis was documented with favorable response to ursodeoxycholic acid treatment. Twenty months later, the patient developed autoimmune hepatitis with elevated aspartate aminotransferase and immunoglobulin G and high titer antinuclear antibody as well as corticosteroid dependency, whereas the antimitochondrial antibody disappeared. The patient's sera initially showed reactivity to three mitochondrial proteins, the 74-, 64-, and 56-kilodalton autoantigens of the 2-oxo acid dehydrogenase complexes, which was characteristic of primary biliary cirrhosis. After developing autoimmune hepatitis, reactivity to the 74- and 64-kilodalton antigens disappeared, whereas reactivity to the 56-kilodalton antigen decreased to low levels. Autoimmune cholangitis and probably other forms of the overlap syndrome may re…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Periodic monitoring of liver tests helps detect patients who are inadequate responders to UDCA after 12 months of therapy, lack of adherence, and the rare patients who go on to develop AIH.
“This helps detect patients who are inadequate responders to UDCA after 12 months of therapy, lack of adherence, and the rare patients who go on to develop AIH.(121,135,224,225)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [224]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 34 · Cited by 104
- Authors
- Colombato, L. A., Alvarez, F., Côté, J., & Huet, P.-M.
- Affiliations
- Hôpital Saint-Luc (CA)
- ORCID
- Colombato, Luis A.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 1994-12
- Volume
- 107
- Issue
- 6
- Pages
- 1839-1843
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W1583668523
- Cited by
- 104
- References
- 34
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 1 · 2018: 1 · 2014: 2 · 2013: 2 · 2012: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- autoimmune cholangiopathy, primary biliary cirrhosis, autoimmune hepatitis, overlap syndrome, cholestasis, antinuclear antibodies, antimitochondrial antibodies, ursodeoxycholic acid, corticosteroid therapy, IgG, disease progression
- MeSH terms
- Antibodies, Antinuclear, Autoantibodies, Autoantigens, Autoimmune Diseases, Bile Duct Diseases, Female, Fluorescent Antibody Technique, Follow-Up Studies, Hepatitis, Humans, Liver Cirrhosis, Biliary, Middle Aged, Mitochondria, Liver, Prednisone, Ursodeoxycholic Acid, Immunoblotting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review